Rhythm Pharmaceuticals, Inc. (RYTM)
NASDAQ: RYTM · Real-Time Price · USD
110.41
-0.62 (-0.56%)
At close: Jul 1, 2026, 4:00 PM EDT
112.23
+1.82 (1.65%)
After-hours: Jul 1, 2026, 5:54 PM EDT
Rhythm Pharmaceuticals Revenue
Rhythm Pharmaceuticals had revenue of $60.11M in the quarter ending March 31, 2026, with 83.81% growth. This brings the company's revenue in the last twelve months to $217.17M, up 58.67% year-over-year. In the year 2025, Rhythm Pharmaceuticals had annual revenue of $189.76M with 45.83% growth.
Revenue (ttm)
$217.17M
Revenue Growth
+58.67%
P/S Ratio
34.84
Revenue / Employee
$524,553
Employees
414
Market Cap
7.57B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 189.76M | 59.63M | 45.83% |
| Dec 31, 2024 | 130.13M | 52.70M | 68.06% |
| Dec 31, 2023 | 77.43M | 53.79M | 227.56% |
| Dec 31, 2022 | 23.64M | 20.48M | 649.46% |
| Dec 31, 2021 | 3.15M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| PTC Therapeutics | 827.11M |
| TG Therapeutics | 700.35M |
| Mirum Pharmaceuticals | 569.61M |
| Protagonist Therapeutics | 74.06M |
| ABIVAX Société Anonyme | 5.67M |
| CG Oncology | 5.07M |
RYTM News
- 15 days ago - Rhythm Pharmaceuticals price target raised to $151 from $143 at Canaccord - TheFly
- 16 days ago - Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026 - GlobeNewsWire
- 16 days ago - Rhythm Pharmaceuticals price target raised to $155 from $144 at Wells Fargo - TheFly
- 17 days ago - Rhythm announces preliminary data from Phase 2 trial of setmelanotide - TheFly
- 18 days ago - Rhythm Pharmaceuticals Transcript: Study result - Transcripts
- 18 days ago - Rhythm Pharmaceuticals Slides: Study result - Filings
- 18 days ago - Rhythm Pharmaceuticals Press release: Study result - Filings
- 18 days ago - Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 - GlobeNewsWire